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Fibrinogen, and factors V and VIII were decreased; the prothrombin time, thrombin time and partial thromboplastin time were prolonged in both intravascular proteolysis and coagulation.
The reliable factors to be tested for the differentiation were the prothrombin determined by the two stage method or by employing prothrombin-free plasma, plasminogen, platelets and the split products derived from either fibrinogen or fibrin. Namely, the platelets and prothrombin were decreased in intravascular coagulation, whereas these factors were normal in proteolytic stage. Plasminogen was low in both fibrinolytic and fibrinogenolytic states, but normal in intravascular coagulation. Basing on the facts that the split products from fibrinogenolysis were heat labile at 56°C for 15 minutes, while those from fibrinolysis were heat-stable, the differentiation between the split products from fibrinogen and fibrin was possible by measuring the thrombin clotting on a mixture of control plasma and heated or non-heated test sample, and by employing the simple radial immune diffusion technique. chloride (10g) and merthiolate (0.025g) were dissolved in distilled water. The solution was made to pH 7.0 and a final volume of 1,000ml; (2) Normal saline.
Consumption
Procedure: Citrate plasma (0.5ml) was mixed with 4.5ml ammonium sulfate. The turbidity was measured at 490 my 3 minutes after adding the ammonium sulfate against the blank which was prepared by adding saline instead of the reagent. The fibrinogen concentration was calculated from the standard curve.
(c) Fibrinogen determination by heating procedure This was done by heating plasma at 56°C for 15 minutes, and the precipitate was measured by using a specific tube of Schulz7 or by colorimetry by phenol reagent.
14. Plasminogen estimation by a modified method of Hedner & Nilsson8, 9 Reagents: (1) 4% Casein; Four g of casein (Hammersten, Merck) were suspended in 1/7.5 M disodium phosphate and heated in a boiling water bath for 20 minutes. The solution was diluted to 100ml with distilled water. (2) Procedure: To a test tube containing 0.5 ml of citrate plasma, 1ml of 0.1 N hydrochloric acid was added to destroy antiplasmin and allowed to stand for 30 minutes at room temperature, followed by neutralization with 1ml of 0.1 N sodium hydroxide. To the resultant reaction mixture 1.5ml of phosphate buffer and 0.5ml of streptokinase (500 units) or urokinase (500 Ploug units) were added and incubated for 5 minutes. The reaction was continued for 1 hour after the addition of 2.5ml of casein, and was stopped by adding 5ml of TCA. The mixture was filtered through the Toyo filter paper No. 5. The optical density was measured at 275 my against the blank which was prepared in the same way except for adding TCA before incubating with casein substrate. The activity was expressed by Kunitz unit.10 15. Antiplasmin assay by a fibrinolytic method Reagents: (1) 0.2% Bovine fibrinogen (Armour) in 1/15 M phosphate buffer pH 7.4, (Soerensen) containing 0.9% sodium chloride, (2) Plasmin activated spontaneously in 50% glycerol-phosphate buffer, (3) Thrombin (Mochida, 100 units/ml normal saline), and (4) Trasylol (Bayer).
Procedure: Into a test tube containing 0.5 ml of plasmin, 0.5 ml of inhibitor (1:10 diluted citrated plasma or standard Trasylol) were added and the mixture was incubated for 10 minutes at 37°C. After incubation time of 8-9 minutes, 0.1ml of thrombin was added. The lysis time was measured after adding 1ml of fibrinogen. The antiplasmin level was calculated from the standard curve which was prepared simultaneously with standard Trasylol.
Preparation of rabbit antiserum against human fibrinogen
Reagents: (1) Human fibrinogen (Kabi) was prepared so as to contain 5 mg in 5 ml of normal saline, (2) Freund's adjuvant, complete (Difco), and (3) sodium azide or mer thiolate.
Procedure: Using a plastic disposable syringe and No.18 needles, 5 ml of complete Freund's adjuvant were taken and added to 5 ml of fibrinogen. Emulsion was prepared by filling and emptying it back into a small beaker repeatedly. It was convenient to use a homogenizer for the preparation of a large amount of emulsion. The emulsion was ready to use when a drop of the emulsion held completely together on the surface of normal saline in a Petri dish.
Each rabbit was injected with 1ml of emulsion in 6 sites sterilized previously with 70% alcohol; each foot pad, the scruff of the neck and the intraperitoneal cavity. The use of antibiotics was recommended to avoid bacterial infection. After the first injection, a minimum of a 2 week period was necessary before administration of challenging dose of the Human fibrinolysin (Lyovac, streptokinase-activated fibrinolysin, 50,000 units, Merck, Sharp and Dohme) was injected into a dog, and the factors of coagulation fibrinolysis system were determined at the given time. The average values obtained in 4 dogs are shown in Fig. 4 . The thrombin time, prothrombin time and thrombotest were prolonged. These changes might be mainly due to decrease in fibrinogen and increase in fibrinogen split products which had an activity to inhibit fibrin polymerization by thrombin. Prothrombin, factor VII and antiplasmin were not changed, while factor V, fibrinogen and plasminogen were markedly decreased. These changes were consistent with those obtained in vitro tests of the above experiment. Platelets were slightly decreased to an average value of 85%, ranging 65-125%. Fibrinogen, prothrombin and factor V were decreased, while factor VII was not changed. No significant change in fibrinolytic system was observed.
II. Differentiation of fi,brinogenolysis products from fibrinolysis products Theoretically, fibrinogenolysis products in fibrinogenolytic state, fibrinolysis products in intravascular coagulation with secondary fibrinolysis and none of the split products in intravascular coagulation which is not associated with secondary fibrinolysis could be detected in patient's plasma. If it is possible to differentiate fibrinogenolysis products from fibrinolysis ones, this may give a decisive clue to differentiate intravascular proteolysis from intravascular coagulation with or without secondary fibrinolysis.
Beller and Maki15 demonstrated that in vitro fibrinogenolysis products were heat-labile, while fibrinolysis ones heat-stabile at 56°C for 15 minutes.
To re-investigate this problem, fibrinogenolysis was induced by incubating 20ml of citrate plasma with 2 nil of `0,000 units streptokinase for various incubation time, and fibrinolysis by incubating 20ml of citrate plasma with 2 ml of a mixture of 20,000 units streptokinase and 10 units of thrombin. The reaction mixture (2 nil) at given incubation time was taken into a tube containing 0.05ml of 500 units Trasylol.
As native material, blood sample from the vasa efferentia of the uterus, which was very high in fibrinolytic activity,16,11 was obtained during gynecological surgery, and incubated for 3-20 hours. The incubated whole blood with sodium citrate (a model of fibrinogenolysis) and one without sodium citrate (a model of fibrinolysis) were subjected to the various tests. Nearly complete or partial fibrinolysis was noted during this incubation time. To make the same condition as in the model of fibrinogenolysis, I volume of 3.8% sodium citrate was added to 9 volumes of the incubated whole blood after incubation finished. The reaction was stopped by adding Trasylol.
The antithrombin activity was determined on a mixture of 0.1ml of control citrate plasma and 0.1ml of heated (56°C for 15 minutes) or unheated sample. The results are shown in Tables 1 and 2 .
The fibrinogen concentration was decreased by incubation of citrate blood depending on difference of samples. Fibrinogen concentration determined by the method of Ratnoff and Menzie was lower than that obtained by the heat precipitation procedure or turbidimetry. The thrombin clotting time was markedly prolonged after incubation. By adding the incubated plasma to control plasma, the thrombin clotting time was increased depending on the fibrinogenolytic activity. This prolongation effect on the thrombin clotting time was corrected by heating the test plasma.
In contrast to the fibrinogenolysis products the influence of the fibrinolysis products on the thrombin clotting time was not marked, and was often shortened. This shortening of the thrombin clotting time might be due to a clot promoting effect of serum or defibrinated plasma. However, the thrombin clotting time of control plasma in the presence of unheated materials (fibrinolysis products). The diameter of immune circle observed by the simple radial immune diffusion technique was markedly decreased after heating in fibrinogenolysis products, while it was slightly increased or not changed in the fibrinolysis products (Fig. 6) . However, the heat-stability of fibrinogenolysis products was increased with prolongation of incubation time and higher plasmin activity, and after reacting with thrombin. 15 and diameter of immune circle of plasma obtained from, incubated model offbrinogenolysis) before and after incubation efferentia of the uterus. of streptokinase in Nos. 6 and 7. clottable protein with thrombin. value of 5 mm indicated that there is no The split products from both fibrinogen and fibrin were sensitively detected by the TRCHIL However, it was difficult to differentiate fibrinolysis products from fibrinogenolysis ones by heating procedure.
DISCUSSION
Regarding the etiology of acute acquired hypofibrinogenemia, there have been controversial discussions about whether this situation results from primary proteo lysis (digestion of fibrinogen and other clotting factors but not of fibrin) or from disseminated intravascular coagulation (defibrination) with or without secondary fibrinolysis. Also a possiblity of fibrinogen consumption due to hemorrhage into extravascular space, e.g., the retroplacental space, has been presented. The treatment of this situation is, therefore, quite different depending on the etiology. An anticoagulant such as heparin should be used for intravascular coagulation, and antiplasmin preparations for intravascular proteolysis. For this reason, it is a very important problem to establish the differential diagnosis between them.
The purpose of this paper is to find out what tests are most sensitive to make a differential diagnosis, and to obtain a correct criterion for the interpretation of laboratory tests in consumption coagulopathy.
Consumption of the clotting factors due to intravascular coagulation results in decrease in fibrinogen, prothrombin, factors V and VIII and platelets, because these factors are consumed during coagulatiom, while the clotting factors called as the serum factor (factors VII, IX and X) are normal 18In consumption coagulopathy due to plasma proteolysis by plasmin, fibrinogen, factors V and VIII are lowered, because these substances are digested by plasmin. Plasminogen is converted to plasmin followed by inactivation with naturally occurring antiplasmin.
As the result, plasminogen is lowered in proteolytic state. 18, 19, 19 As to prothrombin and antiplasmin, there have been controversial discussions.18-22 Our result showed that both prothrombin and antiplasmin were not changed by plasmin. In spite of the insignificant decrease .-in an antiplasmin in the experimental proteolysis, we found frequently a lowered antiplasmin level in clinical cases of pathologic proteolysis. It was therefore suspected that the lowered antiplasmin was not due to secondary change of pathologic proteolysis but a primary factor in a development of proteolysis.
The changes in factors of coagulation-fibrinolysis system in intravascular coagulation and intravascular proteolysis can be summarized as illustrated in Table  3 . The reliable differentiation can be made by measuring platelets and prothrombin determined by the two stage method or by employing prothrombin free plasma.
It has been known that fibrinolysis is very often noted as a secondary response to intravascular coagulation. In this case, split products from fibrin by digestion with plasmin can be detected from patient's plasma. On the other hand, the presence of split products from fibrinogen is indicative of primary proteolysis (fibrinogenolysis). To differentiate the split products from fibrinogen and those from fibrin, the measurement of the thrombin clotting time and the immune assay seem to be effective. It was noted that fraction D from fibrinolysis, which locates immuno electrophoretically in the same position of mother fibrinogen, was heat-stable. On the contrary, it was found that fraction D derived from fibrinogenolysis was heat-labile. The stabilization of fraction D seemed to be due to the presence of thrombin. 15 Lewis and Wilson23 provided evidence that heating inactivated the antithrombin effect of fibrinogenolysis products, whereas fibrinolysis products even without heating had not antithrombin effect. Fibrinolysis products, however, contain thrombin as a contamination, and the antithrombin effect may be masked. The appearance of antithrombin effect after heating fibrinolysis products seemed to be due to inactivation of contaminated thrombin and heat-stability of fibrinolysis products.
It was also noted that diameter of immune circle was decreased in fibrinoge nolysis products but was not changed in fibrinolysis ones. 15 From these facts, fibrinolysis products can be differentiated from fibrinogenolysis products as illustrated in Table 4 .
There are, however, some questions to be discussed.
(1) Since the nature of immune anticoagulant, which is occasionally released in obstetrical condition, has not been clarified completely, it is unknown how this anticoagulant influences the thrombin clotting time method.
(2) Pathologically elevated secondary fibrinolysis may induce simultaneously intravascular proteolysis. In such a combined situation, the differentiation may be difficult. ( 3) The split products derived from both fibrinogen and fibrin, which are formed by digestion with highly active plasmin for a long incubation time, are close in heat-stability.
In other words, fibrinogenolysis products acquire heat-stability after incuba tion with highly active plasmin for a long time. This, however, may not occur in vivo, because (1) excess amount of naturally occurring antiplasmins is present in plasma, and (2) such a strong proteolysis found as in vitro may not develop in vivo.
For these reasons, the reliability of the tests in making the differential diagnosis needs further investigation on clinical materials.
